229 related articles for article (PubMed ID: 12136597)
1. [Effect of combined chemotherapy following the guidelines on treatment for Mycobacterium avium complex pulmonary disease].
Kobashi Y; Okimoto N; Matsushima T; Shigetou E; Kuraoka T; Takeyama H; Eda R; Yano S; Kobayashi K; Ohnishi T; Mori K; Ueda Y; Moritaka T; Nishimura K; Abe T
Kekkaku; 2002 Jun; 77(6):435-41. PubMed ID: 12136597
[TBL] [Abstract][Full Text] [Related]
2. Factors that affect sputum conversion and treatment outcome in patients with Mycobacterium avium-intracellulare complex pulmonary disease.
Ye JJ; Wu TS; Chiang PC; Lee MH
J Microbiol Immunol Infect; 2007 Aug; 40(4):342-8. PubMed ID: 17712469
[TBL] [Abstract][Full Text] [Related]
3. [Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy-- following the guidelines for treatment].
Kobashi Y; Oka M
Kekkaku; 2008 Dec; 83(12):779-84. PubMed ID: 19172823
[TBL] [Abstract][Full Text] [Related]
4. [The clinical study on efficacy of clarithromycin, levofloxacin, and streptomycin for pulmonary Mycobacterium avium-intracellulare complex infection].
Taga S; Ogawa K; Nakagawa T; Tano M
Kekkaku; 2005 Jan; 80(1):1-7. PubMed ID: 15839056
[TBL] [Abstract][Full Text] [Related]
5. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study.
Kobashi Y; Matsushima T
Respiration; 2007; 74(4):394-400. PubMed ID: 16954651
[TBL] [Abstract][Full Text] [Related]
6. [Perspective of pulmonary MAC infection treatment].
Kurashima A
Kekkaku; 2007 Mar; 82(3):195-9. PubMed ID: 17444124
[TBL] [Abstract][Full Text] [Related]
7. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
[TBL] [Abstract][Full Text] [Related]
8. The effect of combined therapy according to the guidelines for the treatment of Mycobacterium avium complex pulmonary disease.
Kobashi Y; Matsushima T
Intern Med; 2003 Aug; 42(8):670-5. PubMed ID: 12924489
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of non-tuberculous pulmonary mycobacteriosis].
Sakatani M; Nakajima Y
Kekkaku; 2006 Jan; 81(1):35-50. PubMed ID: 16479999
[TBL] [Abstract][Full Text] [Related]
10. [A study on the effect of combined chemotherapy on Mycobacterium avium complex pulmonary disease].
Sato K; Ebe T
Kekkaku; 2000 Jul; 75(7):471-6. PubMed ID: 10944891
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy of pulmonary Mycobacterium kansasii infection].
Mizutani S
Kekkaku; 1996 Sep; 71(9):527-31. PubMed ID: 8914388
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic efficacy of macrolide in pulmonary nontuberculous mycobacteriosis].
Tomono K
Kekkaku; 1994 Nov; 69(11):725-32. PubMed ID: 7837727
[TBL] [Abstract][Full Text] [Related]
13. [Outcome of pulmonary Mycobacterium avium complex (MAC) disease treated with clarithromycin (CAM)-containing regimens].
Shirai M; Hayakawa H; Nakano Y; Kuroishi S; Nakano Y; Todate A; Suda T; Chida K
Nihon Kokyuki Gakkai Zasshi; 2004 Oct; 42(10):875-9. PubMed ID: 15566000
[TBL] [Abstract][Full Text] [Related]
14. [The clinical study of clarithromycin for pulmonary Mycobacterium avium-intracellulare complex infection].
Yamamoto M; Kuze F; Sakatani M; Saito H; Shimoide H; Soejima R; Hara K
Kekkaku; 1997 Jan; 72(1):1-7. PubMed ID: 9038009
[TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
16. [Strategies for Mycobacterium avium complex infection control in Japan: how do they improve the present situation?].
Ogawa K; Sano C
Kekkaku; 2013 Mar; 88(3):355-71. PubMed ID: 23672176
[TBL] [Abstract][Full Text] [Related]
17. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex.
Griffith DE; Brown BA; Cegielski P; Murphy DT; Wallace RJ
Clin Infect Dis; 2000 Feb; 30(2):288-92. PubMed ID: 10671330
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease.
Hasegawa N; Nishimura T; Ohtani S; Takeshita K; Fukunaga K; Tasaka S; Urano T; Ishii K; Miyairi M; Ishizaka A
Chest; 2009 Dec; 136(6):1569-1575. PubMed ID: 19542259
[TBL] [Abstract][Full Text] [Related]
19. The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease.
Fujita M; Kajiki A; Tao Y; Miyazaki M; Ouchi H; Harada E; Ikegame S; Matsumoto T; Uchino J; Watanabe K; Nakanishi Y
J Infect Chemother; 2012 Apr; 18(2):146-51. PubMed ID: 21927844
[TBL] [Abstract][Full Text] [Related]
20. The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study.
Kadota JI; Kurashima A; Suzuki K
J Infect Chemother; 2017 May; 23(5):293-300. PubMed ID: 28254517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
